Navigation Links
Novel therapeutic agents provide hope for patients with hard-to-treat blood disorders
Date:12/9/2012

h and without the T3151 mutation build on previous evidence and imply that ponatinib is a TKI that may work across a wide range of mutations associated with TKI resistance and also in instances where mutations are not detected.

Remarkably, complete cytogenetic response (no Ph+ cells measured in the body) was achieved in 46 percent of patients with chronic phase CML, with higher response rates observed in patients who were exposed to fewer prior TKIs and those with shorter disease duration. The therapy was also well tolerated in all cohorts, as evidenced by the minimal toxicities observed. The most common adverse events observed were skin toxicity (including rash or dry skin), elevation of pancreatic enzymes and/or pancreatitis, and myelosuppression (a side effect of cancer treatment that lowers blood cell count). At the time of analysis, 52 percent of patients remained on the therapy. These results demonstrate ponatinib's efficacy in CML and Ph+ALL patients with no other viable treatment options.

"This therapy may be able to transform highly fatal forms of leukemia into a curable disease in these patients we have simply never had any treatment produce such high rates of durable response in such a heavily treated group of patients," said Jorge Cortes, MD, lead author, Professor of Medicine, Deputy Chair of the Department of Leukemia, and Chief of the CML and AML Sections at The University of Texas MD Anderson Cancer Center in Houston. "Our next step is to test ponatinib's potential as an initial therapy in an attempt to prevent the occurrence of relapse that may decrease the prospects of a normal lifespan for patients."

Dr. Cortes will present this study in an oral presentation on Sunday, December 9, at 4:30 p.m. EST at the Georgia World Congress Center in Room A411-A412, Level 4, Building A

Phase I/II Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethaso
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Researchers develop novel 3-D culture system for inflammatory breast cancer
2. ACNP: Novel NMDA receptor modulator significantly reduces depression scores within hours
3. Scripps Florida scientists uncover a novel cooperative effort to stop cancer spread
4. Novel mechanism through which normal stromal cells become cancer-promoting cells identified
5. Novel breast screening technology increases diagnostic accuracy
6. UNC, Vanderbilt discover a new live vaccine approach for SARS and novel coronaviruses
7. Moffitt Cancer Center researchers identify novel metabolic programs driving aggressive brain tumors
8. Novel treatment strategies for epilepsy
9. Taiho Pharmaceutical unveils data on 8 novel anticancer compounds
10. Researchers ID potential patient population who may benefit from novel anti-platelet treatment
11. Undertreatment of common heart condition persists despite rapid adoption of novel therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Health Dialog, a leading provider of ... has received Patient Oriented Accreditation from the National ... Management (DM) Programs for asthma, congestive heart failure, ... and diabetes. This marks the 12th continuous year ... Management (DM) Programs, reaffirming Health Dialog’s focus and ...
(Date:12/15/2014)... Dec. 14, 2014 (HealthDay News) -- Expert pilots process ... explains why they make better decisions during landings, a ... most difficult techniques for pilots to master, and 36 ... fatal crashes occur during final approach and landing. ... and 12 moderately experienced pilots while they were at ...
(Date:12/15/2014)... 2014 Kathy McAfee, America's Marketing Motivator, ... Awards in the category of Best Blog 2014. McAfee ... her weekly career blog Networking Ahead which ... professionals elevate their talent and influence through better networking, ... her book Networking Ahead for Business, has been motivating ...
(Date:12/15/2014)... OR (PRWEB) December 15, 2014 ... seeks to bring attention to restrictive state laws ... position paper on this important area of public ... Laws Can Compromise the Integrity of Independent Review, ... and access of independent peer review determinations can ...
(Date:12/15/2014)... Bacteroides is becoming the indicator of choice for ... prevalent than coliforms, it cannot reproduce in the presence of ... Key Benefits of the new Bacteroides Sewage Screen:, ... Eliminates false positives from coliforms naturally occurring in the environment ... Maintain the same sampling method with results as quick ...
Breaking Medicine News(10 mins):Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Study Shows Why Expert Pilots Are Experts 2Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2
... the gold-standard treatment for postoperative and chronic cancer pain ... showing that opiate-based painkillers can stimulate the growth and ... argument and demonstrate how shielding lung cancer cells from ... cell-culture and mouse models. The reports--to be presented ...
... people appear to be fearless, navigating busy sidewalks and ... a cane as a guide. The reason they can ... some circumstances, blindness can heighten other senses, helping individuals ... UCLA Department of Neurology have confirmed that blindness causes ...
... ... , ... Ziosoft®, Inc. http://www.ziosoftinc.com -- a leader in advanced visualization and analysis software for ... marketing, effective November 16., , , , ,Most recently, Royea served as vice president of ...
... , LOUISVILLE, Ky., Nov. 18 ... for its Carewise® Health consumer education and support program ... establishes quality standards for the healthcare industry. , ... education and support accreditation back in 2005, and this ...
... young adults with single-ventricle congenital heart disease who ... sildenafil, a drug used to treat erectile dysfunction ... Hospital of Philadelphia. Single-ventricle defects are ... heart,s ability to pump blood. Examples include tricuspid ...
... , , WASHINGTON, Nov. 18 ... a wholly owned subsidiary of ULLICO Inc., a privately ... Prescription Solutions will provide pharmacy benefit management services to ... union trust funds, union employers and their members with ...
Cached Medicine News:Health News:Common pain relief medication may encourage cancer growth 2Health News:Common pain relief medication may encourage cancer growth 3Health News:UCLA study shows brain's ability to reorganize 2Health News:UCLA study shows brain's ability to reorganize 3Health News:Ziosoft Announces the Appointment of Rob Royea, Vice President, Sales and Marketing 2Health News:SHPS Receives Re-Accreditation from URAC for Consumer Education and Support Program 2Health News:Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 2Health News:Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 3
(Date:12/15/2014)... 12, 2014 Research and Markets ... http://www.researchandmarkets.com/research/ms3j8c/cardiac ) has announced the addition of the ...  report to their offering. Global Guidewires sector is ... North America accounts for nearly 35% ... claims approximately 25% (2018). Asia-Pacific ...
(Date:12/15/2014)... TARRYTOWN, N.Y. and BRIDGEWATER, N.J. ... Inc. (NASDAQ: REGN) and Sanofi US (EURONEXT: SAN and ... heart disease organizations to launch Cholesterol Counts , ... know about cholesterol, their numbers, and the risks associated ... to visit www. CholesterolCounts .com to take ...
(Date:12/15/2014)... MARCOS, Texas , Dec. 15, 2014  Stephen ... dot manufacturer Quantum Materials Corp (OTCQB:QTMM), will ... Center for Quantum Materials (RCQM) on December 16th, 2014. ... exploration of exotic nanomaterials in attracting top faculty and ... Rice to collaborate on research. "We ...
Breaking Medicine Technology:Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 2Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 3
... , , , , , , BANGALORE, India ... unique strategy. This is based on the following,elements: , , ... Sino-Indian focus, - Flexible co-development model availability, ... Experience of early stage life science company product development, - ...
... , , CAMBRIDGE, Mass. , ... it has reached an agreement with the U.S. Food and Drug ... trial for Vascugel®, an investigational new drug for the prevention of ... Special Protocol Assessment (SPA) procedure. Pervasis expects to initiate the study ...
Cached Medicine Technology:Infinitus Clinical Research Consolidates- Sino-Indian CRO Enhances Core Capabilities 2Infinitus Clinical Research Consolidates- Sino-Indian CRO Enhances Core Capabilities 3Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R) 2Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R) 3Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R) 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: